Intra-Cellular ticks higher as J&J forecasts early Q2 close

Posted on by wpadmin
Johnson & Johnson Inc. Canada"s facility in Markham, On, Canada.

JHVEPhoto

  • Intra-Cellular Therapies (NASDAQ:ITCI) edged higher by 0.6% as Johnson & Johnson (JNJ) said it expects its planned more than $14 billion acquisition to close early in the second quarter.
  • Johnson & Johnson (JNJ) made the early Q2 forecast on

Leave a Reply

Your email address will not be published. Required fields are marked *